Abiomed Breethe OXY-1 System

2020: A product yield on the market

At the end of October, 2020 Abiomed provided the portable system of artificial blood circulation and oxygenation which will help doctors to treat patients from COVID-19 and other people with cardiogenic shock or respiratory insufficiency. The artificial lung received the name Abiomed Breethe OXY-1 System.

Abiomed added a portable device for extracorporal membrane oxygenation (EKMO) to the portfolio in April, 2020 thanks to acquisition of Breethe company. Now EKMO Breethe supplements the heart pump Impella of production Abiomed - the combination received the name ECpella.

Abiomed provided an artificial lung for infected with a coronavirus

According to the producer, for the last decade doctors successfully used Impella devices and EKMO Breethe at treatment about 10,000 patients with cardiogenic shock. Effects of a koronavirusny infection sharply increased demand for similar combinations for support of the cardiovascular and respiratory systems.

Abiomed purchased Breethe at the beginning of a pandemic, and in August got permission to Impella use in case of emergency for unloading of the left ventricle at patients with COVID-19.

"Unloading of the left ventricle starts a cascade of favorable reactions. It allows a myocardium to have a rest and helps it to be recovered. But at the same time unsatisfied is a need of the patient for oxygenation therefore the possibility of release of the combined ECpella device was a matter of time. Survival with natural recovery of function of heart should be an ultimate goal of treatment of all these patients", - the CEO of Abiomed Michael Minogue considers.

Researchers note that Impella RP increases survival of patients by 73% when using within 48 hours after the beginning of cardiogenic shock. At the same time Abiomed draws the attention of potential clients to rather compact, universal construction of the system and its portability.^[1]

Notes